Insulet Corp PODD
We take great care to ensure that the data presented and summarized in this overview for INSULET CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PODD
View all-
Vanguard Group Inc Valley Forge, PA8.2MShares$1.69 Billion0.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.56MShares$1.56 Billion0.3% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$1.24 Billion0.02% of portfolio
-
State Street Corp Boston, MA2.92MShares$601 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA1.99MShares$409 Million0.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$343 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA1.66MShares$341 Million0.03% of portfolio
-
Baillie Gifford & CO1.44MShares$297 Million0.2% of portfolio
-
Morgan Stanley New York, NY1.39MShares$286 Million0.02% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.34MShares$276 Million0.06% of portfolio
Latest Institutional Activity in PODD
Top Purchases
Top Sells
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Transactions at PODD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,500
-10.43%
|
$298,500
$199.96 P/Share
|
|
Jun 10
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,131
-12.91%
|
$404,890
$190.43 P/Share
|
|
Jun 10
2024
|
Timothy J Scannell Director |
SELL
Open market or private sale
|
Direct |
7,000
-16.44%
|
$1,330,000
$190.51 P/Share
|
|
Jun 04
2024
|
Michael R Minogue Director |
BUY
Bona fide gift
|
Indirect |
843
+15.45%
|
-
|
|
Jun 04
2024
|
Michael R Minogue Director |
SELL
Bona fide gift
|
Direct |
843
-37.92%
|
-
|
|
Jun 04
2024
|
Luciana Borio Director |
SELL
Open market or private sale
|
Direct |
360
-9.84%
|
$65,520
$182.58 P/Share
|
|
May 31
2024
|
James Hollingshead President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,973
-8.72%
|
$703,221
$177.19 P/Share
|
|
May 28
2024
|
Timothy J Scannell Director |
SELL
Open market or private sale
|
Direct |
3,300
-7.19%
|
$594,000
$180.9 P/Share
|
|
May 28
2024
|
Timothy J Scannell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,267
+10.57%
|
$602,811
$33.31 P/Share
|
|
May 22
2024
|
Timothy C. Stonesifer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+32.62%
|
-
|
|
May 22
2024
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+23.61%
|
-
|
|
May 22
2024
|
Michael R Minogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+38.3%
|
-
|
|
May 22
2024
|
Flavia Pease Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+32.62%
|
-
|
|
May 22
2024
|
Timothy J Scannell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+4.76%
|
-
|
|
May 22
2024
|
Luciana Borio Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+27.39%
|
-
|
|
May 22
2024
|
Wayne A.I. Frederick Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+21.44%
|
-
|
|
May 22
2024
|
Jessica Hopfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+4.88%
|
-
|
|
May 01
2024
|
Ana Maria Chadwick EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
13,214
+50.0%
|
-
|
|
Feb 28
2024
|
Prem Singh SVP, Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-1.64%
|
$14,670
$163.6 P/Share
|
|
Feb 28
2024
|
Shacey Petrovic Director |
SELL
Open market or private sale
|
Direct |
11,609
-81.89%
|
$1,880,658
$162.92 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 64.9K shares |
|---|---|
| Bona fide gift | 10.3K shares |
| Exercise of conversion of derivative security | 49.9K shares |
| Open market or private purchase | 5.55K shares |
| Bona fide gift | 21.4K shares |
|---|---|
| Open market or private sale | 62.4K shares |
| Payment of exercise price or tax liability | 9.16K shares |